凱普生物(300639.SZ)修訂2020年度A股定增方案 涉發行價格及定價原則、限售期等
格隆匯2月17日丨凱普生物(300639.SZ)公佈,公司第四屆董事會第五次會議召開,逐項審議通過了《關於修訂公司2020年度創業板非公開發行A股股票方案的議案》。
根據《中華人民共和國公司法》《中華人民共和國證券法》及《創業板上市公司證券發行管理暫行辦法》(2020年修正)等相關創業板上市公司非公開發行股票的規定,同意公司向包括公司實際控制人之一、董事及高級管理人員管秩生在內的不超過35名特定對象非公開發行股票,募集資金總額預計不超過人民幣10.5億元(含本數)。
此次非公開發行的定價基準日為發行期首日。發行價格不低於定價基準日前二十個交易日公司股票交易均價(計算公式為:定價基準日前20個交易日股票交易均價=定價基準日前20個交易日股票交易總額÷定價基準日前20個交易日股票交易總量)的80%。
此次非公開發行股票完成後,公司實際控制人之一、董事及高級管理人員管秩生認購的此次發行的股票自發行結束之日起18個月內不得轉讓,其他特定對象認購的本次發行的股票自發行結束之日起6個月內不得轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.